Results 1 to 10 of about 51,741 (305)

Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: a population-based study of 2.3 million vaccine recipients [PDF]

BMC Medicine, 2022
Background In view of accumulating case reports of thyroid dysfunction following COVID-19 vaccination, we evaluated the risks of incident thyroid dysfunction following inactivated (CoronaVac) and mRNA (BNT162b2) COVID-19 vaccines using a population-based
Carlos King Ho Wong, David Tak Wai Lui, Xi Xiong, Celine Sze Ling Chui, Francisco Tsz Tsun Lai, Xue Li, Eric Yuk Fai Wan, Ching Lung Cheung, Chi Ho Lee, Yu Cho Woo, Ivan Chi Ho Au, Matthew Shing Hin Chung, Franco Wing Tak Cheng, Kathryn Choon Beng Tan, Ian Chi Kei Wong   +14 more
doaj   +2 more sources

Effectiveness of COVID‐19 Vaccination in Reducing Severity Among SARS‐CoV‐2 Infected Patients: A Prospective Study From Iraq [PDF]

Health Sci Rep
ABSTRACT Background Coronavirus disease 2019 (COVID‐19) is a lethal global pandemic that originated in Wuhan, China at the end of 2019. As with other viral infectious diseases, the introduction of an effective vaccine is crucial for stopping the spread of the pandemic. In Iraq the COVID‐19 vaccination campaign started on March 2, 2021.
Al‐Obaidi A, Ibrahim M, Al‐Qaseer A.
europepmc   +2 more sources

A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting [PDF]

Scientific Reports
This 22-month cohort study investigated the durability and dynamics of humoral immune responses in 327 Malaysians vaccinated with either CoronaVac or BNT162b2 in early 2021, monitored up to 52 weeks following a BNT162b2 booster. Using the ImmuSAFE™ COVID 
Aini Syahida Mat Yassim, Anis Atifah Mohd Hisham, Nik Nur Atiqah Nik Daud, Nur Diana Anuar, Ti-Myen Tan, Rapeah Suppian, Mat Jusoh Siti Asmaa, Amiratul Aifa Mohamad Asri, Maryam Azlan, Nur Suhaila Idris, Rosediani Muhamad, Mohd Nor Norazmi   +11 more
doaj   +2 more sources

Antispike IgG antibody decay after immunisation with fractional versus full booster doses of COVID-19 vaccines: a 6-month longitudinal analysis of the FRACT-COV trial in Brazil [PDF]

BMJ Public Health
Objectives To compare antispike IgG levels over a period of 182 days of follow-up in healthy adults who received full or fractional booster doses of BNT162b2 or AZD1222 after completing a primary series of Sinovac, BNT162b2 or AZD1222.Design Double-blind,
Haley Hedlin, Vivek Charu, Di Lu, Patricia Vieira da Silva, Julio Croda, Amy Zhang, Farah Qamar, Joelle I Rosser, Juliana Barros Verruck, Marco Antonio Moreira Puga, Roberto Dias de Oliveira, Victor Ritter, Blake Shaw, Jessica Couvillion Seidman, Alice Scott Carter, Stephen Luby, Denise Garrett   +16 more
doaj   +2 more sources

Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial [PDF]

Infectious Diseases and Therapy
Introduction COVID-19 continues to cause substantial health burden, particularly among vulnerable populations. Vaccines remain a vital tool in preventing severe disease outcomes. As the causative pathogen, severe acute respiratory syndrome coronavirus 2 (
Oyeniyi Diya, Juleen Gayed, Francine S. Lowry, Hua Ma, Vishva Bangad, Federico Mensa, Jing Zou, Xuping Xie, Yanping Hu, Mark Cutler, Todd Belanger, David Cooper, Xia Xu, Robin Mogg, Özlem Türeci, Uǧur Şahin, Kena A. Swanson, Kayvon Modjarrad, Annaliesa S. Anderson, Alejandra Gurtman, Nicholas Kitchin   +20 more
doaj   +2 more sources

Effectiveness of a third dose of COVID-19 vaccines against delta variant of SARS-COV-2: A Serbian cohort study [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2023
Introduction/Objective. The duration of vaccine-induced protection against SARS-CoV-2 is shown to be limited. The aim of this study was to assess vaccine effectiveness (VE) of a third dose of four different COVID-19 vaccines during Delta variant ...
Đorđević Nataša, Matić Sanja, Milovanović Dragan, Stefanović Srđan, Popović Suzana, Todorović Danijela, Đurđević Predrag, Sazdanović Predrag, Antić Vasilije, Lončar Slavica, Bukumira Slavica, Radenković Marko, Šusteršić Tijana, Filipović Nenad, Baskić Dejan   +14 more
doaj   +1 more source

Effectiveness of NVX-CoV2373 and BNT162b2 COVID-19 Vaccination in South Korean Adolescents. [PDF]

Pediatr Infect Dis J
Gwak E, Choe SA, Kim K, Bolormaa E, Gschwend MH, Fix J, Vadivale M, Rousculp MD, Choe YJ.   +8 more
europepmc   +3 more sources

Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP [PDF]

, 2023
Objective To compare the effectiveness of the BNT162b2 mRNA (Pfizer-BioNTech) and mRNA-1273 (Moderna) covid-19 vaccines during the booster programme in England. Design Matched cohort study, emulating a comparative effectiveness trial.
Andrews, Colm D, Bacon, Sebastian CJ, Curtis, Helen J, Goldacre, Ben, Hernán, Miguel A, Horne, Elsie MF, Hulme, William J, Keogh, Ruth H, MacKenna, Brian, Mehrkar-Asl, Amir, Morley, Jessica, Palmer, Tom M, Parker, Edward PK, Sterne, Jonathan AC, Walker, Alex J, Walker, Venexia, Williamson, Elizabeth J   +16 more
core   +2 more sources

Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants [PDF]

, 2022
Vaccination shows efficacy in protecting from COVID-19, but regime and dosing optimization is still ongoing. Here the authors show that BNT162b2, mRNA-1273, or their combination with ChAdOx1 induces similar antibody responses, and those receiving three ...
Belik, Milja, Häkkinen, Hanni K., Ivaska, Lauri, Jalkanen, Pinja, Julkunen, Ilkka, Kakkola, Laura, Kantele, Anu, Kolehmainen, Pekka, Laine, Larissa, Lempainen, Johanna, Lundberg, Rickard, Miettinen, Simo, Naves, Rauno A., Ortamo, Eeva, Pakkanen, Sari H., Pasternack, Arja, Reinholm, Arttu, Ritvos, Mikael A., Ritvos, Olli, Sironen, Tarja, Skön, Marika, Tahtinen, Paula A., Vapalahti, Olli, Väisänen, Elina, Österlund, Pamela   +24 more
core   +1 more source

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines

Human Vaccines & Immunotherapeutics, 2023
Introduction of primary COVID-19 vaccination has helped reduce severe disease and death caused by SARS-CoV-2 infection. Understanding the protection conferred by heterologous booster regimens informs alternative vaccination strategies that enable ...
Moe H. Kyaw, Julia Spinardi, Ling Zhang, Helen May Lin Oh, Amit Srivastava   +4 more
doaj   +1 more source